The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
Primary Purpose
Asthma
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
montelukast sodium
beclomethasone
Placebo inhaler
placebo tablet
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring chronic asthma
Eligibility Criteria
Inclusion Criteria:
- Female patients tested negative for pregnancy and agreed to use appropriate contraceptives through out the study
- Patient was a nonsmoker
- Patient was in good general health (except for asthma)
Exclusion Criteria:
- Patient was hospitalized
- Patient was female who was less than 8 weeks postpartum or breast feeding
- Patient planned to move or vacation away during the study
- Patient had major surgery within 4 weeks the past 4 weeks
- Patient has donated blood or participated in a clinical trial within the past 4 weeks
- Patient was a regular user or recent abuser of alcohol or illicit drugs
- Patient was 40% over or under normal weight for height
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
1
2
3
4
Arm Description
Montelukast + Beclomethasone
Montelukast + Placebo inhaler
Placebo tablet + Beclomethasone
Placebo tablet + Placebo inhaler
Outcomes
Primary Outcome Measures
Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) in Patients With Chronic Asthma
Mean percent change from baseline in FEV1 in patients with chronic asthma averaged over 16 weeks for the Beclo and MK+ Beclo groups and averaged over last 10 weeks for the Placebo and MK groups
Mean Change From Baseline in Daytime Symptom Score on the Daytime Asthma Symptoms Diary in Patients With Chronic Asthma
The daily daytime symptom score was determined by averaging the daily scores (the patient scored his/her symptoms [from 0 (best) to 6 (worst)] on a daily basis.) for the four questions on the Daytime Asthma Symptoms Diary.
The average daytime symptom score for the visit was determined by averaging the daily symptom scores over all days between two consecutive visits.
Secondary Outcome Measures
Mean Percent Change From Baseline in Total Daily Beta-agonist Medication Use
Beta-agonist medication use from the daytime and overnight asthma symptoms diaries for each 24-hour period was added to determine the daily total number of puffs used. The average daily number of puffs for the visit was determined as the average daily number of puffs over all days between consecutive visits.
Mean Change From Baseline in Morning Peak Flow Rate (PEFR) in Patients With Chronic Asthma
Morning PEFR was measured in triplicate immediately upon arising before taking any medication and the best value recorded on the overnight asthma symptoms diary. The mean morning PEFR for the visit was determined by averaging all valid PEFR measurements for the days between consecutive visits.
Mean Change From Baseline in Nocturnal Asthma Score on the Overnight Asthma Symptoms Diary in Nocturnal Asthmatic Patients Only
Mean change from baseline in Nocturnal asthma score; the patient scored his/her symptoms [from 0 (best) to 3 (worst)] on a daily basis. Responses to the question, "Did you wake up with asthma symptoms?" (no, once, more than once, awake "all night"), were assigned numerical values (0, 1, 2, 3, respectively).
The average score for the visit was determined by averaging the daily scores over all days between consecutive visits.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00911547
Brief Title
The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
Official Title
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 2-Period, Parallel-Group Study to Assess the Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
March 1995 (undefined)
Primary Completion Date
April 1996 (Actual)
Study Completion Date
May 1996 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Organon and Co
4. Oversight
5. Study Description
Brief Summary
This study will investigate the additive effect of montelukast (MK0476) taken along with inhaled beclomethasone versus inhaled beclomethasone alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
chronic asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
642 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Montelukast + Beclomethasone
Arm Title
2
Arm Type
Experimental
Arm Description
Montelukast + Placebo inhaler
Arm Title
3
Arm Type
Experimental
Arm Description
Placebo tablet + Beclomethasone
Arm Title
4
Arm Type
Placebo Comparator
Arm Description
Placebo tablet + Placebo inhaler
Intervention Type
Drug
Intervention Name(s)
montelukast sodium
Other Intervention Name(s)
MK0476
Intervention Description
10 mg tablet taken once daily at bedtime for 16 weeks
Intervention Type
Drug
Intervention Name(s)
beclomethasone
Intervention Description
200 ug inhaled, taken twice daily for 16 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo inhaler
Intervention Description
placebo inhaler taken twice daily for 16 weeks
Intervention Type
Drug
Intervention Name(s)
placebo tablet
Intervention Description
placebo tablet taken once daily at bedtime for 16 weeks
Primary Outcome Measure Information:
Title
Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) in Patients With Chronic Asthma
Description
Mean percent change from baseline in FEV1 in patients with chronic asthma averaged over 16 weeks for the Beclo and MK+ Beclo groups and averaged over last 10 weeks for the Placebo and MK groups
Time Frame
Baseline & over 16 weeks for the Beclomethasone (Beclo) and Montelukast (MK) + Beclo groups and over last 10 weeks for the Placebo and MK groups
Title
Mean Change From Baseline in Daytime Symptom Score on the Daytime Asthma Symptoms Diary in Patients With Chronic Asthma
Description
The daily daytime symptom score was determined by averaging the daily scores (the patient scored his/her symptoms [from 0 (best) to 6 (worst)] on a daily basis.) for the four questions on the Daytime Asthma Symptoms Diary.
The average daytime symptom score for the visit was determined by averaging the daily symptom scores over all days between two consecutive visits.
Time Frame
Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups
Secondary Outcome Measure Information:
Title
Mean Percent Change From Baseline in Total Daily Beta-agonist Medication Use
Description
Beta-agonist medication use from the daytime and overnight asthma symptoms diaries for each 24-hour period was added to determine the daily total number of puffs used. The average daily number of puffs for the visit was determined as the average daily number of puffs over all days between consecutive visits.
Time Frame
Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups
Title
Mean Change From Baseline in Morning Peak Flow Rate (PEFR) in Patients With Chronic Asthma
Description
Morning PEFR was measured in triplicate immediately upon arising before taking any medication and the best value recorded on the overnight asthma symptoms diary. The mean morning PEFR for the visit was determined by averaging all valid PEFR measurements for the days between consecutive visits.
Time Frame
Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups
Title
Mean Change From Baseline in Nocturnal Asthma Score on the Overnight Asthma Symptoms Diary in Nocturnal Asthmatic Patients Only
Description
Mean change from baseline in Nocturnal asthma score; the patient scored his/her symptoms [from 0 (best) to 3 (worst)] on a daily basis. Responses to the question, "Did you wake up with asthma symptoms?" (no, once, more than once, awake "all night"), were assigned numerical values (0, 1, 2, 3, respectively).
The average score for the visit was determined by averaging the daily scores over all days between consecutive visits.
Time Frame
Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups
10. Eligibility
Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female patients tested negative for pregnancy and agreed to use appropriate contraceptives through out the study
Patient was a nonsmoker
Patient was in good general health (except for asthma)
Exclusion Criteria:
Patient was hospitalized
Patient was female who was less than 8 weeks postpartum or breast feeding
Patient planned to move or vacation away during the study
Patient had major surgery within 4 weeks the past 4 weeks
Patient has donated blood or participated in a clinical trial within the past 4 weeks
Patient was a regular user or recent abuser of alcohol or illicit drugs
Patient was 40% over or under normal weight for height
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
10588598
Citation
Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999 Dec;160(6):1862-8. doi: 10.1164/ajrccm.160.6.9803042.
Results Reference
result
Learn more about this trial
The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
We'll reach out to this number within 24 hrs